Hereditary nonpolyposis colorectal cancer medical therapy

	Hereditary Nonpolyposis Colorectal Cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hereditary nonpolyposis colorectal cancer medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hereditary nonpolyposis colorectal cancer medical therapy
CDC on Hereditary nonpolyposis colorectal cancer medical therapy
Hereditary nonpolyposis colorectal cancer medical therapy in the news
Blogs on Hereditary nonpolyposis colorectal cancer medical therapy
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]Ali Akram, M.B.B.S.[3]

Overview

There is no medical treatment for hereditary nonpolyposis colorectal cancer. However, hereditary nonpolyposis colorectal cancer patients should consider diet optimization and pharmacological prevention.

Medical Therapy

Patients with hereditary nonpolyposis colorectal cancer should consider the following options of medical management:

Diet Optimization

Patients with high risk of colorectal cancer should consider a low fat diet with limitations concerning red meat.^[1]^[2]
Dietary approaches should consider the inclusion of high fiber and rich in cellulose foods.

Pharmacological Prevention

Drugs lowering the risk of colorectal cancer include:^[3]^[4]^[5]^[6]

The real value of these drugs in cancer prevention in hereditary nonpolyposis colorectal cancer cannot be excluded, but is not definitely proven. Further studies are needed to find the optimal dosage and duration of therapy for these medications.

References

↑ W. C. Willett, M. J. Stampfer, G. A. Colditz, B. A. Rosner & F. E. Speizer (1990). "Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women". The New England journal of medicine. 323 (24): 1664–1672. doi:10.1056/NEJM199012133232404. PMID 2172820. Unknown parameter |month= ignored (help)
↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter |month= ignored (help)
↑ H. T. Lynch & J. Lynch (2000). "Lynch syndrome: genetics, natural history, genetic counseling, and prevention". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18 (21 Suppl): 19S–31S. PMID 11060321. Unknown parameter |month= ignored (help)
↑ Matthew B. Yurgelun & Heather Hampel (2018). "Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention". American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): 101–109. doi:10.1200/EDBK_208341. PMID 30231390. Unknown parameter |month= ignored (help)
↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter |month= ignored (help)
↑ Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S; et al. (2011). "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial". Lancet. 378 (9809): 2081–7. doi:10.1016/S0140-6736(11)61049-0. PMC 3243929. PMID 22036019.

Template:WikiDoc Sources

[1] W. C. Willett, M. J. Stampfer, G. A. Colditz, B. A. Rosner & F. E. Speizer (1990). "Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women". The New England journal of medicine. 323 (24): 1664–1672. doi:10.1056/NEJM199012133232404. PMID 2172820. Unknown parameter |month= ignored (help)

[2] Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter |month= ignored (help)

[3] H. T. Lynch & J. Lynch (2000). "Lynch syndrome: genetics, natural history, genetic counseling, and prevention". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18 (21 Suppl): 19S–31S. PMID 11060321. Unknown parameter |month= ignored (help)

[4] Matthew B. Yurgelun & Heather Hampel (2018). "Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention". American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): 101–109. doi:10.1200/EDBK_208341. PMID 30231390. Unknown parameter |month= ignored (help)

[5] Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter |month= ignored (help)

[pmid22036019-6] Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S; et al. (2011). "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial". Lancet. 378 (9809): 2081–7. doi:10.1016/S0140-6736(11)61049-0. PMC 3243929. PMID 22036019.

[1]

[2]

[3]

[4]

[5]

[6]